ClinicalTrials.Veeva

Menu

Evaluation of Quality of Life in Patients With Type 1 Diabetes Mellitus During the Covid-19 Pandemic

G

Gazi University

Status

Completed

Conditions

Type 1 Diabetes Mellitus
Covid19

Treatments

Other: Online Survey

Study type

Observational

Funder types

Other

Identifiers

NCT04558645
91610558-604.01.02

Details and patient eligibility

About

During the COVID-19 pandemic, the time spent at the home of patients has increased because of national quarantine policies and patients' fear of getting sick. For this reason, in this ongoing process, patients have been unable to go to work regularly due to their chronic diseases (being on administrative leave) and their fear of going out. These reasons have prevented being physically active. The aim of the study is to evaluate the physical activity level, quality of life, glucose control, anxiety, depression, fear of hypoglycemia and loneliness perceptions of patients with type 1 diabetes mellitus during the COVID-19 pandemic period and compared with healthy controls.

Enrollment

118 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Having been diagnosed with Type 1 Diabetes Mellitus
  • Willing to participate in the study
  • Participants whose native language is Turkish

Exclusion criteria

  • Unwilling to participate in the study
  • Having a cognitive disorder
  • Not being literate
  • Individuals who do not have sufficient knowledge and functional levels to fill out the online form

Trial design

118 participants in 2 patient groups

Patients with type 1 diabetes mellitus
Description:
Patients with Type 1 diabetes mellitus willing to participate in the study
Treatment:
Other: Online Survey
Healthy controls
Description:
Healthy controls without chronic disease willing to participate in the study
Treatment:
Other: Online Survey

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems